The market for glucagon-like peptide (glp)-1 agonists utilized for weight reduction has experienced swift expansion lately, projected to increase from a valuation of $13.38 billion in 2024 to $15.5 billion in 2025, reflecting a compound annual growth rate (CAGR) of 15.9%
A product prescribed against a non-weight indication cardiovascular risk reduction, obstructive sleep apnea, MASH, or type 2 diabetes is assessed on that indication rather than as a weight-loss agent
Frontiers in CAR-T cell therapy for autoimmune diseases
Build Lean Muscle and Explosive Strength
(History + Background) GHRP-2 stands for Growth Hormone Releasing Peptide-2 a synthetic hexapeptide developed to stimulate the bodys natural release of growth hormone (GH)
[DOI] [PMC free article] [PubMed] 315.Agostinis P, Vantieghem A, Merlevede W, de Witte PA